RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of the new treatment
proposed in this study. Conducting a prospective study "CNS-2015" in patients with PDLBCL CNS
made it possible to achieve 2-year EFS, DFS and OS of 83%, 83% and 88%, respectively. The
presence of early relapses of the disease has now led to the need to find an alternative
program for patients with PDLBCL CNS. In the new "CNS-2021" protocol, lenalidomide was
included in the R-MPV program in order to intensify the induction stage. In the conditioning
regimen, thiotepa was replaced by carmustine, due to its significant CNS bioavailability. In
order to possibly prevent early relapses, an anti-PD-1 inhibitor (nivolumab) was used as
maintenance therapy.